VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vericel Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$40.37+0.24 (+0.60%)
Close on Oct 19, 2026
- Market cap
- $2.11B
- P/E (TTM)
- 96.1
- Dividend yield
- –
Share price
+$5.05 (+14.30%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Vericel Corp grew revenue 23.0% to $306.30M over the twelve months to Jun 30, 2026. Operating income rose 1428.5% to $18.24M, moving the operating margin from 0.5% to 6.0%. Free cash flow was $61.66M.
Revenue
$306.30M
+23.0% vs. a year earlier
Operating income
$18.24M
+1428.5% vs. a year earlier
Free cash flow
$61.66M
TTM Q2 2026
EPS, diluted
$0.42
+500.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.11B
- P/E ratio
- 96.1
- Price to sales
- 6.89
- Price to book
- 5.71
- Dividend yield
- –
- Free cash flow yield
- 2.92%
Fundamentals
- Revenue
- $306.30M
- Net income
- $24.22M
- EPS, diluted
- $0.42
- Free cash flow
- $61.66M
- Book value per share
- $7.07
- Diluted shares
- 52M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$306.30M+23.0% YoY
Gross profit
$228.38M+24.8% YoY
Operating income
$18.24M+1428.5% YoY
Net income
$24.22M+240.8% YoY
EPS, diluted
$0.42+500.0% YoY
Free cash flow
$61.66M
Reported periodTrailing twelve months